Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;22(1):54-59.
doi: 10.1111/hiv.12941. Epub 2020 Sep 2.

Universal test and treat in relation to HIV disease progression: results from a stepped-wedge trial in Eswatini

C E Boeke  1 , S Khan  2 , F Walsh  1 , A Hettema  2 , C Lejeune  2 , D Spiegelman  3 , V Okello  4 , J Harwell  1 , S Mazibuko  4 , T Bärnighausen  3   5   6
Affiliations
Free article

Universal test and treat in relation to HIV disease progression: results from a stepped-wedge trial in Eswatini

C E Boeke et al. HIV Med. 2021 Jan.
Free article

Abstract

Objectives: Universal test and treat (UTT) is recommended for people living with HIV (PLHIV) to reduce morbidity/mortality and minimize transmission. However, concerns exist that this strategy may lead to more crowded hospitals, longer wait times and poorer service, adversely impacting health outcomes for clients with severe disease. We assessed how UTT was related to markers of disease progression in PLHIV overall and specifically among clients with low CD4 count/high World Health Organization (WHO) stage.

Methods: The analysis was conducted using data from a stepped-wedge trial of UTT in 14 government-managed health facilities in Eswatini from 2014 to 2017. Disease progression was defined as CD4 count falling below 200 cells/µL or baseline value, > 10% weight loss, body mass index (BMI) dropping below 18.5, incident tuberculosis (TB) or HIV-related death; these outcomes also were assessed individually. We assessed multivariate Cox proportional hazard models overall and specifically among clients with CD4 count < 350 cells/μL or WHO stage 3-4 at enrolment.

Results: Eight hundred and seven of 3176 clients demonstrated at least one marker of disease progression over 2339 person-years of follow-up. Overall, 62.4% of clients were female; 57.2% were < 35 years old. Compared to clients not exposed to UTT, those exposed to UTT had a lower rate of disease progression overall [adjusted hazard ratio (aHR) 0.60; 95% confidence interval (CI) 0.46-0.78] and a lower rate of CD4 decline (aHR 0.40; 95% CI 0.27-0.58). When the analysis was limited to clients with CD4 count < 350 cells/μL or WHO stage 3-4, UTT was not associated with disease progression (aHR 0.92; 95% CI 0.66-1.29).

Conclusions: UTT reduced HIV disease progression overall and was not detrimental for clients with more severe disease.

Keywords: Africa; Eswatini; advanced disease; disease progression; universal test and treat.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva, World Health Organization (WHO), 2016.
    1. Okello V. Memorandum: Re: Scale up of test and start strategy in all ART providing facilities. In: Health Mo, ed. Swaziland, 2016.
    1. Cohen MS, Chen YQ, McCauley M et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016; 375: 830-839.
    1. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 373: 808-822.
    1. INSIGHT START Study Group, Lundgren JD, Babiker AG et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373: 795-807.

Publication types

Substances